Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:UNC5B-PSAP

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: UNC5B-PSAP
	FusionPDB ID: 96844
	FusionGDB2.0 ID: 96844
		Hgene	Tgene
	Gene symbol	UNC5B	PSAP
	Gene ID	219699	729238
	Gene name	unc-5 netrin receptor B	surfactant protein A2
	Synonyms	UNC5H2\|p53RDL1	COLEC5\|PSAP\|PSP-A\|PSPA\|SFTP1\|SFTPA2B\|SP-2A\|SP-A\|SPA2\|SPAII
	Cytomap	10q22.1	10q22.3
	Type of gene	protein-coding	protein-coding
	Description	netrin receptor UNC5Bp53-regulated receptor for death and life protein 1protein unc-5 homolog 2protein unc-5 homolog Btransmembrane receptor Unc5H2unc-5 homolog 2unc-5 homolog B	pulmonary surfactant-associated protein A235 kDa pulmonary surfactant-associated proteinalveolar proteinosis proteincollectin 5surfactant, pulmonary-associated protein A2A
	Modification date	20200313	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000335350, ENST00000373192,	ENST00000394934, ENST00000394936,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	5 X 7 X 5=175	25 X 26 X 8=5200
	# samples	8	30
	** MAII score	log2(8/175*10)=-1.12928301694497 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(30/5200*10)=-4.11547721741994 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: UNC5B [Title/Abstract] AND PSAP [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: UNC5B [Title/Abstract] AND PSAP [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	UNC5B(72972821)-PSAP(73594262), # samples:1
Anticipated loss of major functional domain due to fusion event.	UNC5B-PSAP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. UNC5B-PSAP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. UNC5B-PSAP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. UNC5B-PSAP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:72972821/chr10:73594262)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across UNC5B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PSAP (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000335350	UNC5B	chr10	72972821	+	ENST00000394936	PSAP	chr10	73594262	-	3173	495	416	2029	537
ENST00000335350	UNC5B	chr10	72972821	+	ENST00000394934	PSAP	chr10	73594262	-	3176	495	416	2035	539
ENST00000373192	UNC5B	chr10	72972821	+	ENST00000394936	PSAP	chr10	73594262	-	2816	138	59	1672	537
ENST00000373192	UNC5B	chr10	72972821	+	ENST00000394934	PSAP	chr10	73594262	-	2819	138	59	1678	539

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000335350	ENST00000394936	UNC5B	chr10	72972821	+	PSAP	chr10	73594262	-	0.003531009	0.996469
ENST00000335350	ENST00000394934	UNC5B	chr10	72972821	+	PSAP	chr10	73594262	-	0.003792427	0.9962076
ENST00000373192	ENST00000394936	UNC5B	chr10	72972821	+	PSAP	chr10	73594262	-	0.003135732	0.99686426
ENST00000373192	ENST00000394934	UNC5B	chr10	72972821	+	PSAP	chr10	73594262	-	0.003374772	0.9966252

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for UNC5B-PSAP

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
UNC5B	chr10	72972821	PSAP	chr10	73594262	138	26	ALLLCWDPRLSQAALAGPVLGLKECT
UNC5B	chr10	72972821	PSAP	chr10	73594262	495	26	ALLLCWDPRLSQAALAGPVLGLKECT

Top

Potential FusionNeoAntigen Information of UNC5B-PSAP in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

UNC5B-PSAP_72972821_73594262.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:02	PRLSQAAL	0.78	0.5997	7	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:02	DPRLSQAAL	0.9957	0.6539	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B14:02	DPRLSQAAL	0.9718	0.9105	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B14:01	DPRLSQAAL	0.9718	0.9105	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B08:01	DPRLSQAAL	0.9682	0.5702	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B08:09	DPRLSQAAL	0.9258	0.7945	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:03	DPRLSQAAL	0.8588	0.7402	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:03	QAALAGPVL	0.8405	0.9152	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:04	QAALAGPVL	0.7171	0.9779	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:02	QAALAGPVL	0.7171	0.9779	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:04	DPRLSQAAL	0.5886	0.8765	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:02	DPRLSQAAL	0.5886	0.8765	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B81:01	QAALAGPVL	0.5293	0.6359	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B82:01	DPRLSQAAL	0.2004	0.5267	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B48:01	SQAALAGPVL	0.978	0.7652	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:22	AALAGPVLGL	0.9392	0.6047	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B81:01	WDPRLSQAAL	0.87	0.6981	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:38	AALAGPVLGL	0.8549	0.7765	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:05	WDPRLSQAAL	0.8399	0.6611	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:13	AALAGPVLGL	0.8328	0.7279	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:02	WDPRLSQAAL	0.8231	0.7822	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:20	AALAGPVLGL	0.8164	0.5398	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:35	AALAGPVLGL	0.7977	0.5436	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B13:01	SQAALAGPVL	0.7779	0.9829	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A03:25	AALAGPVLGLK	0.9994	0.5027	12	23
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B78:01	DPRLSQAA	0.9944	0.6191	6	14
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B42:01	PRLSQAAL	0.9645	0.5287	7	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:19	QAALAGPVL	0.9987	0.9884	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:07	QAALAGPVL	0.9983	0.9863	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:08	QAALAGPVL	0.9982	0.9038	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B42:02	DPRLSQAAL	0.9743	0.5868	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B42:01	DPRLSQAAL	0.9707	0.5777	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B14:03	DPRLSQAAL	0.9348	0.8757	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C12:12	QAALAGPVL	0.9281	0.9628	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C08:13	QAALAGPVL	0.9062	0.9875	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C08:04	QAALAGPVL	0.9062	0.9875	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:04	DPRLSQAAL	0.8206	0.5501	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:12	DPRLSQAAL	0.7997	0.6657	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C08:03	QAALAGPVL	0.7568	0.9916	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:12	QAALAGPVL	0.7171	0.9779	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:12	DPRLSQAAL	0.5886	0.8765	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B39:10	QAALAGPVL	0.5857	0.9601	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B39:10	DPRLSQAAL	0.4959	0.9272	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B42:02	WDPRLSQAAL	0.9511	0.6098	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B42:01	WDPRLSQAAL	0.9408	0.6016	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:04	WDPRLSQAAL	0.9208	0.7559	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:12	WDPRLSQAAL	0.8758	0.8459	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B48:03	SQAALAGPVL	0.8511	0.5186	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B73:01	DPRLSQAALA	0.7121	0.8555	6	16
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A03:01	AALAGPVLGLK	0.9994	0.5027	12	23
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B78:02	DPRLSQAA	0.9936	0.7279	6	14
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:22	PRLSQAAL	0.78	0.5997	7	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:04	QAALAGPVL	0.9989	0.9883	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:03	QAALAGPVL	0.9989	0.9883	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:05	QAALAGPVL	0.9972	0.9253	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:17	QAALAGPVL	0.997	0.9742	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:09	DPRLSQAAL	0.9961	0.6239	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:22	DPRLSQAAL	0.9957	0.6539	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:02	QAALAGPVL	0.995	0.9744	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B08:18	DPRLSQAAL	0.9682	0.5702	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C03:06	QAALAGPVL	0.9544	0.9891	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C16:04	QAALAGPVL	0.9499	0.9846	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:13	QAALAGPVL	0.9393	0.8315	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:24	DPRLSQAAL	0.8665	0.7074	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:13	QAALAGPVL	0.8412	0.9194	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C16:01	QAALAGPVL	0.8078	0.9844	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-C08:01	QAALAGPVL	0.7568	0.9916	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:22	QAALAGPVL	0.7473	0.5555	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:09	QAALAGPVL	0.7171	0.9779	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B51:06	QAALAGPVL	0.7042	0.6838	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B08:12	DPRLSQAAL	0.6211	0.7275	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:09	DPRLSQAAL	0.5886	0.8765	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B67:01	DPRLSQAAL	0.5794	0.8673	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B82:02	DPRLSQAAL	0.2004	0.5267	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B18:07	DPRLSQAAL	0.1256	0.7871	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B40:21	QAALAGPVL	0.1208	0.7935	11	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B35:43	DPRLSQAAL	0.0235	0.6578	6	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B15:73	SQAALAGPVL	0.9851	0.9448	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B15:30	SQAALAGPVL	0.9781	0.8564	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:26	WDPRLSQAAL	0.9322	0.6184	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B39:02	SQAALAGPVL	0.9287	0.8982	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-A02:03	AALAGPVLGL	0.9267	0.656	12	22
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:09	WDPRLSQAAL	0.8772	0.7839	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B40:12	SQAALAGPVL	0.8511	0.5186	10	20
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B07:22	WDPRLSQAAL	0.8231	0.7822	5	15
UNC5B-PSAP	chr10	72972821	chr10	73594262	495	HLA-B40:21	SQAALAGPVL	0.7851	0.5867	10	20

Top

Potential FusionNeoAntigen Information of UNC5B-PSAP in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of UNC5B-PSAP

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1324	DPRLSQAALAGPVL	UNC5B	PSAP	chr10	72972821	chr10	73594262	495

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of UNC5B-PSAP

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1324	DPRLSQAALAGPVL	-7.15543	-7.26883
HLA-B14:02	3BVN	1324	DPRLSQAALAGPVL	-4.77435	-5.80965
HLA-B52:01	3W39	1324	DPRLSQAALAGPVL	-6.80875	-6.92215
HLA-B52:01	3W39	1324	DPRLSQAALAGPVL	-4.20386	-5.23916
HLA-A11:01	4UQ2	1324	DPRLSQAALAGPVL	-7.5194	-8.5547
HLA-A11:01	4UQ2	1324	DPRLSQAALAGPVL	-6.9601	-7.0735
HLA-A24:02	5HGA	1324	DPRLSQAALAGPVL	-7.52403	-7.63743
HLA-A24:02	5HGA	1324	DPRLSQAALAGPVL	-5.82433	-6.85963
HLA-B27:05	6PYJ	1324	DPRLSQAALAGPVL	-3.28285	-4.31815
HLA-B44:05	3DX8	1324	DPRLSQAALAGPVL	-5.91172	-6.94702
HLA-B44:05	3DX8	1324	DPRLSQAALAGPVL	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of UNC5B-PSAP

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
UNC5B-PSAP	chr10	72972821	chr10	73594262	10	20	SQAALAGPVL	GCCAAGCAGCTCTAGCCGGCCCGGTCCTTG
UNC5B-PSAP	chr10	72972821	chr10	73594262	11	20	QAALAGPVL	AAGCAGCTCTAGCCGGCCCGGTCCTTG
UNC5B-PSAP	chr10	72972821	chr10	73594262	12	22	AALAGPVLGL	CAGCTCTAGCCGGCCCGGTCCTTGGACTGA
UNC5B-PSAP	chr10	72972821	chr10	73594262	12	23	AALAGPVLGLK	CAGCTCTAGCCGGCCCGGTCCTTGGACTGAAAG
UNC5B-PSAP	chr10	72972821	chr10	73594262	5	15	WDPRLSQAAL	GGGACCCGAGGCTGAGCCAAGCAGCTCTAG
UNC5B-PSAP	chr10	72972821	chr10	73594262	6	14	DPRLSQAA	ACCCGAGGCTGAGCCAAGCAGCTC
UNC5B-PSAP	chr10	72972821	chr10	73594262	6	15	DPRLSQAAL	ACCCGAGGCTGAGCCAAGCAGCTCTAG
UNC5B-PSAP	chr10	72972821	chr10	73594262	6	16	DPRLSQAALA	ACCCGAGGCTGAGCCAAGCAGCTCTAGCCG
UNC5B-PSAP	chr10	72972821	chr10	73594262	7	15	PRLSQAAL	CGAGGCTGAGCCAAGCAGCTCTAG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of UNC5B-PSAP

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	UNC5B-PSAP	chr10	72972821	ENST00000335350	chr10	73594262	ENST00000394934	TCGA-EW-A1OY

Top

Potential target of CAR-T therapy development for UNC5B-PSAP

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to UNC5B-PSAP

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to UNC5B-PSAP

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)